REGN Filings — Regeneron Pharmaceuticals, Inc. - FilingSpy
REGN
Regeneron Pharmaceuticals, Inc.
A fully integrated biotech that discovers and manufactures medicines for serious diseases, best known for EYLEA (for retinal conditions), Dupixent (for allergic and inflammatory diseases), and cancer drug Libtayo. Founded in 1988 by neurologist Leonard Schleifer and scientist George Yancopoulos, the company got its name by blending "regenerating neurons" with "gene" — reflecting its early dream of rebuilding damaged brain cells. It now grows drug-making cells in huge bioreactors at sites in New York and Ireland, and taps its own genetics center to find new drug targets.
Q2 2026 revenue rose 16.7% to $4.29B as Dupixent profit share offset a 45% EYLEA U.S. sales drop
profits carried Regeneron through another steep decline this quarter. rose 16.7% to $4,290.7M and rose 19.8% to $1,293.5M, while fell 4.5% to $12.23 as higher R&D and IPR&D costs weighed on . The business now rests on Dupixent and as EYLEA erodes.
Key takeaways
rose 51% to $2,170M, lifting total 16.7% to $4,290.7M as and profits grew.
U.S. fell 45% to $412M from biosimilar competition and patient transition, while U.S. net sales rose 52% to $596M.
fell 6.8% to $1,296.9M and fell 4.5% to $12.23 as R&D expenses rose 15% to $1,630M and rose to $127M from $10M on new collaboration payments.
Section summaries
Management's Discussion and Analysis
Q2 2026 revenue rose 17% to $4.29B driven by Dupixent profit share, but net income fell 7% on higher R&D and IPR&D costs.
⌄
Total revenues grew 17% to $4.29B, primarily from a 51% increase in collaboration to $2.17B, reflecting higher and profits.
on net product sales declined to 78% from 83%, hit by unabsorbed manufacturing costs from a temporary Limerick, Ireland production interruption.
Global net product sales increased 30% to $489M on higher volumes.
fell 29.0% to $813.0M and fell 38.1% to $572.8M .
What changed
Q2 2026 U.S. and sales: the flagged 25% Q2 2025 EYLEA decline widened to 45% ($412M), while EYLEA HD rose 52% to $596M, up from $393M a year earlier.
profit share via Sanofi collaboration: the $1.28B Q2 2025 figure grew to $2,170M in Q2 2026, continuing to offset losses.
pre-filled syringe and odronextamab CRLs from third-party fill/finish inspections remain unresolved as of this filing.
Q2 2026 operating and of $813.0M and $572.8M came in below the $1,144.4M and $925.4M Q2 2025 levels, not recovering toward them.
on net product sales was 78% in Q2 2026 versus 83% in Q2 2025, with the Limerick halt and write-offs continuing after the 76% Q1 2026 low.
Since the FY2025 10-K, additional biosimilars are expected in H2 2026 and the risk factors now cite Most-Favored-Nation Pricing agreements and Sanofi litigation as live threats.
What to watch
Q3 2026 U.S. and net product sales as additional biosimilars launch in H2 2026
Q3 2026 and profit share after the $2,170M Q2 figure
Resolution of the odronextamab and pre-filled syringe Complete Response Letters
Q3 2026 on net product sales to see if the 78% figure recovers after Limerick interruption
U.S. rose 52% to $596M, while U.S. fell 45% to $412M due to competitive pressures and patient transition to EYLEA HD.
Global net product sales increased 30% to $489M on higher volumes.
R&D expenses rose 15% to $1.63B, driven by higher clinical manufacturing costs and increased spending on fianlimab, cenvacibart/amrecibart, and other programs.
Acquired IPR&D expenses surged to $127M from $10M, mainly due to up-front and opt-in payments for new collaborations.
on net product sales declined to 78% from 83%, impacted by unabsorbed manufacturing costs from a temporary production interruption in Limerick, Ireland.
Quantitative and Qualitative Disclosures About Market Risk
Our market risks, and the way we manage them, are summarized in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (filed February 4, 2026). There have been no material chan…
⌄
Our market risks, and the way we manage them, are summarized in Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (filed February 4, 2026). There have been no material changes to our market risks or to our management of such risks as of June 30, 2026.
The information called for by this item is incorporated herein by reference to the information set forth in Note 12 to our Condensed Consolidated Financial Statements included in this report.
⌄
The information called for by this item is incorporated herein by reference to the information set forth in Note 12 to our Condensed Consolidated Financial Statements included in this report.
Regeneron's revenue is heavily dependent on EYLEA HD, EYLEA, and Dupixent, facing significant biosimilar competition, pricing pressures, and regulatory risks.
⌄
Net product sales of and represented 25% of total revenues for H1 2026, with EYLEA U.S. sales declining 41% due to competition and other factors.
collaboration , mostly from profits, accounted for 48% of total revenues; litigation with Sanofi over commercialization information could disrupt the collaboration.
The Inflation Reduction Act's Medicare Drug Price Negotiation Program and U.S. Government Agreements on may reduce prices and reimbursement for key products.
FDA Complete Response Letters for odronextamab and the pre-filled syringe, citing third-party manufacturing deficiencies, have delayed potential approvals.
versions of have launched in the U.S. and other markets, and additional biosimilars are expected, threatening market exclusivity and .
Manufacturing interruptions at the Limerick, Ireland facility and reliance on single-source suppliers and third-party providers pose supply chain risks.